Lanean...
CSIG-32. ACTIVATED Trk/Met PATHWAY IS A NOVEL RESISTANCE MECHANISM FOR CDK4/6 INHIBITORS THAT CAN BE TARGETED WITH A SPECIFIC SMALL MOLECULE INHIBITOR
Glioblastoma (GBM) is among the deadliest malignancies, with an extremely poor prognosis. Clinical trials with single agents have largely proven disappointing largely due to tumor heterogeneity and cancer stem cell plasticity. Often times, single agent treatments induce cancer stem cell reprogrammin...
Gorde:
| Argitaratua izan da: | Neuro Oncol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692333/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.226 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|